Clearside Biomedi (CLSD)

$0.32 -0.03 (-8.61%)
Market Cap 26.06M
Revenue (ttm) 1.66M
Net Income (ttm) -34.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,069.28%
Debt to Equity Ratio 0.00
Volume 1,351,424
Avg Vol 5,568,396
Day's Range N/A - N/A
Shares Out 78.51M
Stochastic %K 52%
Beta 2.11
Analysts Sell
Price Target $4.00

Company Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 270 3631
Fax: 678 270 4033
Address:
900 North Point Parkway, Suite 200, Alpharetta, United States
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 23 at 7:06 PM
$CLSD has anyone seen anything to indicate Change of Control can't be resolved in early march followed shortly thereafter by the auction that will in all likelihood yield quite a bit more than the current ask of .57
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 23 at 4:01 PM
$CLSD A monday morning survey: Anyone here 1. Buying 2. Selling 3. Neither Since I asked i'll go first: buying
1 · Reply
buyandsold
buyandsold Feb. 22 at 2:48 AM
$CLSD our dockets have produced more paper than the Epstein files, and they have just as many predators.
0 · Reply
JaumeIII
JaumeIII Feb. 19 at 9:33 AM
$CLSD I have no doubt that cls-ax would have performed much better than the $OCUL trial with all comers and every 6 month dosing…with zero chance of endophthalmitis. Maybe some pharma co will see this and pick it up. The risk/ reward is worth it if you are flush!
1 · Reply
Qora
Qora Feb. 18 at 3:16 AM
$CLSD @jbal @rando321456 Any chance of a decent or ok outcome at this point?
1 · Reply
jbal
jbal Feb. 17 at 10:46 PM
$CLSD The ocul call was a bizarre dramatic reading of a script by the ceo and 2 "KOLs" that took a full 45 minutes. They took 3 questions, non-answered them like politicians, and cut it off at 1:05 because of some unknown time constraint, as if they only put one hour on the meter. The presentation was a masterclass of putting lipstick on on a pig. CLS-AX slightly outperformed axpaxli at 24 weeks, in a much harder to treat cohort. CLSD didn't reveal much detail in the ODYSSEY safety profile, but Axpaxli's is a train wreck, as hard the the CEO tries to spin it otherwise. None of this is of any value to CLSD shareholders now as George drove it off a cliff months ago. No new bidders are going to look at the data and palm smack their forehead and realize that the presumption that ocul's insert was a category killer was a fantasy birthed by their CEO.
2 · Reply
rando321456
rando321456 Feb. 17 at 12:04 PM
$OCUL $CLSD Brutal sorry guys, the CLS-AX readout was the canary in the coal mine for axitinib. I was hoping they would show some numbers that wowed.
1 · Reply
rando321456
rando321456 Feb. 16 at 8:57 PM
$CLSD It'll be super interesting if ocul not bidding here is a tell that their results are bad and more broadly that TKIs as a class of drug do not interface with wet AMD as well as everyone hoped. Just from first principles one would think they would bid a million or two to prevent the only other way to treat Wet AMD with their API from being developed any further. That is if they truly believed their results would drive a multi-billion dollar drug. Though given what's been observed from Clearside this will be a billion dollar class of drugs and the people in the company are so overwhelmingly incompetent that they could not do anything with that.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 16 at 5:34 PM
$CLSD when the auction resumes whats the chances we have more bidders at the table abbv rgnx? etc
0 · Reply
UgoGreg
UgoGreg Feb. 16 at 4:34 PM
$CLSD https://youtu.be/arPHi-VXB6c
0 · Reply
Latest News on CLSD
No data available.
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 23 at 7:06 PM
$CLSD has anyone seen anything to indicate Change of Control can't be resolved in early march followed shortly thereafter by the auction that will in all likelihood yield quite a bit more than the current ask of .57
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 23 at 4:01 PM
$CLSD A monday morning survey: Anyone here 1. Buying 2. Selling 3. Neither Since I asked i'll go first: buying
1 · Reply
buyandsold
buyandsold Feb. 22 at 2:48 AM
$CLSD our dockets have produced more paper than the Epstein files, and they have just as many predators.
0 · Reply
JaumeIII
JaumeIII Feb. 19 at 9:33 AM
$CLSD I have no doubt that cls-ax would have performed much better than the $OCUL trial with all comers and every 6 month dosing…with zero chance of endophthalmitis. Maybe some pharma co will see this and pick it up. The risk/ reward is worth it if you are flush!
1 · Reply
Qora
Qora Feb. 18 at 3:16 AM
$CLSD @jbal @rando321456 Any chance of a decent or ok outcome at this point?
1 · Reply
jbal
jbal Feb. 17 at 10:46 PM
$CLSD The ocul call was a bizarre dramatic reading of a script by the ceo and 2 "KOLs" that took a full 45 minutes. They took 3 questions, non-answered them like politicians, and cut it off at 1:05 because of some unknown time constraint, as if they only put one hour on the meter. The presentation was a masterclass of putting lipstick on on a pig. CLS-AX slightly outperformed axpaxli at 24 weeks, in a much harder to treat cohort. CLSD didn't reveal much detail in the ODYSSEY safety profile, but Axpaxli's is a train wreck, as hard the the CEO tries to spin it otherwise. None of this is of any value to CLSD shareholders now as George drove it off a cliff months ago. No new bidders are going to look at the data and palm smack their forehead and realize that the presumption that ocul's insert was a category killer was a fantasy birthed by their CEO.
2 · Reply
rando321456
rando321456 Feb. 17 at 12:04 PM
$OCUL $CLSD Brutal sorry guys, the CLS-AX readout was the canary in the coal mine for axitinib. I was hoping they would show some numbers that wowed.
1 · Reply
rando321456
rando321456 Feb. 16 at 8:57 PM
$CLSD It'll be super interesting if ocul not bidding here is a tell that their results are bad and more broadly that TKIs as a class of drug do not interface with wet AMD as well as everyone hoped. Just from first principles one would think they would bid a million or two to prevent the only other way to treat Wet AMD with their API from being developed any further. That is if they truly believed their results would drive a multi-billion dollar drug. Though given what's been observed from Clearside this will be a billion dollar class of drugs and the people in the company are so overwhelmingly incompetent that they could not do anything with that.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 16 at 5:34 PM
$CLSD when the auction resumes whats the chances we have more bidders at the table abbv rgnx? etc
0 · Reply
UgoGreg
UgoGreg Feb. 16 at 4:34 PM
$CLSD https://youtu.be/arPHi-VXB6c
0 · Reply
Clifden
Clifden Feb. 13 at 2:08 PM
$CLSD Jimmy Dunne from Piper Sandler was on CNBC today with Joe Kiernan . Too bad they didn’t have an investor call in session. Would of asked him WTF happened to this POS investment even they couldn’t offload. I’m still invested with all my shares and took a good beating. Maybe I can take my wife, kids, grandkids out for a nice steak/lobster dinner when this settles. Other than that its Mickey D’s 😂. Management F’d this from the get go as they have done with numerous other small biotechs. Milk the investor and ride off into the sunset a millionaire. It’s all on me, Bio investings a bitch !! GLTA
0 · Reply
Qora
Qora Feb. 12 at 6:29 PM
$CLSD guys without being too unnecessarily pessimistic, what are we really looking at. I want a reorg so I can keep my shares. Is this well in the cards or not? Thanks.
1 · Reply
buyandsold
buyandsold Feb. 11 at 5:37 PM
$CLSD if only the price action were true LOL must be someone trying to make their acccount green on a day of biotech disaster. It worked for me, so thanks
1 · Reply
liquidx_rs3
liquidx_rs3 Feb. 9 at 7:56 PM
$CLSD What options do we have as stock holder now?
1 · Reply
maphere
maphere Feb. 7 at 5:29 PM
$CLSD still promoting... event this weekend.
1 · Reply
rando321456
rando321456 Feb. 7 at 1:40 AM
$CLSD It'll be interesting if CLS-AX will wind up serving as a smoking gun if OCUL posts bad results as the EYPT CEO is speculating. In the back of my head I cannot get over that they did not put out swim lanes fot the phase 2 trial. If we live in a rational world there had to have been some issue with how TKIs interact with the disease. My hypothesis is that they are too slow to act and Clearside's rescue rate spiked up post the 6 month reinjection mark. This is why they specifically designed their phase 3 around treating their patients earlier. It may be the case that these things have to be given with an antivegf shot which would drastically reduce their value proposition.
0 · Reply
Dasmin
Dasmin Feb. 5 at 5:13 PM
$CLSD When will we find out what will happen to our shares
1 · Reply
buyandsold
buyandsold Feb. 5 at 6:06 AM
$CLSD This is a BK that should never have been. Take lowest possible bid, subtract highest possible legal fees, and I think you are still above 70 cents. Management are criminals.
1 · Reply
maphere
maphere Feb. 5 at 3:45 AM
$CLSD old habit... positive article. Also makes me wonder on future patents effect on deal making. https://pubmed.ncbi.nlm.nih.gov/40982423/
0 · Reply
rando321456
rando321456 Feb. 4 at 5:17 AM
$CLSD The drama continues with the latest docket drop, god this is so pathetic.
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Feb. 1 at 1:37 PM
$CLSD isn't there some data due from one of the partners in the next month or two?
1 · Reply
jbal
jbal Jan. 31 at 9:27 PM
$CLSD No surprises at the hearing. Merits of the claims weren't argued. HCR claimed CLSD surrepticiously transfered the royalties over the cap and this triggered a coc. Said they first learned of it from the SHB purchase agreement. (That was 1/9). CLSD disagrees that a CoC was triggered. Can't contnue auction because uncertainty will chill bidding. They first heard of HCR's CoC claim the morning of the auction (1/20). HCR objected to an accelerated schedule for arguements, wants 30 days. Says "the race here is to get on with an insider led stalking horse bid being promulgated by the debtor's chief medical officer". HCR's interests "are in the royalty sub being run effectively so that it can get the royalty streams that it has purchased. It has no other interest here other than getting the benefit of its investment". Hearing March 4th.
1 · Reply